RT Journal Article
SR Electronic
T1 Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil (DCF-RT) for Patients With Potentially Resectable Esophageal Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4929
OP 4935
DO 10.21873/anticanres.15999
VO 42
IS 10
A1 SAKAI, MAKOTO
A1 SOHDA, MAKOTO
A1 UCHIDA, SHINTARO
A1 YAMAGUCHI, ARISA
A1 WATANABE, TAKAYOSHI
A1 SAITO, HIDEYUKI
A1 UBUKATA, YASUNARI
A1 NAKAZAWA, NOBUHIRO
A1 KURIYAMA, KENGO
A1 SANO, AKIHIKO
A1 OGAWA, HIROOMI
A1 YOKOBORI, TAKEHIKO
A1 NODA, SHIN-EI
A1 OHNO, TATSUYA
A1 SHIRABE, KEN
A1 SAEKI, HIROSHI
YR 2022
UL http://ar.iiarjournals.org/content/42/10/4929.abstract
AB Background/Aim: We evaluated the long-term outcome of docetaxel, cisplatin, and 5-fluorouracil as combination chemoradiotherapy (DCF-RT) for patients with potentially resectable esophageal cancer (EC) in clinical settings. Patients and Methods: Twenty-eight patients with potentially resectable thoracic EC were included in this study. Chemotherapy consisted of intravenous docetaxel at 50 mg/m2 (day 1), CDDP at 60 mg/m2 (day 1), and 5-FU at 600 mg/m2 (days 1 to 4), repeated every four weeks for two cycles along with radiotherapy (60 Gy in 30 fractions). Potentially resectable esophageal cancer was defined as clinical stage (cStage) I, II, III, and IV with supraclavicular lymph node metastasis [M1(Lym)]. Results: The overall complete response (CR) rate was 88.5%. The 5-year overall survival (OS) rates for cStage I, cStage II-III, and IV [M1(lym)] patients were 79.5%, 76.2%, and 50.0%, respectively. The most frequent grade 3 or 4 acute toxicities were leucopenia (85.7%), neutropenia (78.5%), and febrile neutropenia (FN) (21.4%). The rate of any grade 3 or 4 late toxicity was 7.7%. Conclusion: DCF-RT demonstrated a satisfactory CR rate and OS with a higher rate of FN for potentially resectable thoracic EC patients. Prophylactic treatment with granulocyte-colony-stimulating factor and antibiotics may be appropriate supportive care for patients undergoing DCF-RT.